University of Houston partners with health system to provide COVID-19 protective equipment

covid heroes

Aaron McEuen of the University of Houston's Gerald D. Hines College of Architecture and Design answered the call for creating medical face shields for Harris Health System. Photo via uh.edu

A Houston health system was in need of protective personal equipment, or PPE, when they reached out to a local academic institution for support.

Harris Health System tapped the University of Houston to make medical face shields for doctors and nurses at the system's two hospitals — Ben Taub and Lyndon B. Johnson.

"Face shields are one of our most challenging pieces of protective equipment to get during these times of need," says Chris Okezie, vice president of system operations at Harris Health System, in a news release. "They're also the most effective equipment to protect our front-line staff."

One college on campus is particularly equipped to build things, and that's the Gerald D. Hines College of Architecture and Design — specifically the college's Burdette Keeland Jr. Design Exploration Center. It took only a day for the center to build a prototype. Harris Health then made an initial order of 500 masks.

The lab uses universal laser cutters to create the semi-circle of plastic for the shield — the machines can cut 10 pieces in less than 3 minutes. Then, it can be assembled manually. Aaron McEuen, instructional lab manager at the center, is leading the efforts.

"Honestly, it's nice to be productive. I know a lot of people are cooped up in their houses," he says. "We're lucky to have the opportunity to contribute."

One challenge McEuen is facing is procuring the raw materials for the shields. as shipping and delivery times are slower during the pandemic. Despite the obstacles, Harris Health System's president and CEO, Dr. Esmaeil Porsa, is grateful for the support and effort.

"This is a great example of how people of this great city and county come together to address a common and dire need," says Porsa in the release. "I want to personally thank the staff and leadership of University of Houston for stepping up and leading the way to help Harris Health care for our communities in the safest possible way."

Through a $4 million grant, the city of Houston will be able to provide mental health treatment to at-risk students. Educational First Steps/Facebook

City of Houston and local health care organizations receive $4M to treat mental health in students

Help granted

The city of Houston just received a major opportunity to help grow access to mental health treatment in children.

Thanks to a four-year $4 million grant from the United States Substance Abuse and Mental Health Services Administration, the city and its partner, Baylor College of Medicine, are launching the Be-Well Be-Connected program that provides at-risk students age six to 17 years old with mental health treatment.

The program will be led by Dr. Laurel Williams, associate professor of psychiatry at Baylor, division head for child and adolescent psychiatry and chief of psychiatry at Texas Children's Hospital. The treatment will include cognitive behavioral intervention for students with bipolar disorder and first episode psychosis, according to the release. The services will be provided in the child's home, which will ensure compliance.

"We do not have many places in Houston that have this capability to provide this level of intensity of services," Williams says in the release. "Having in-home therapy can allow the young person to stay engaged in their community and in their schools, which can promote wellness and reduction in symptoms burden more quickly."

Other Houston health centers, including Texas Children's Hospital, Harris Health System, Menninger Clinic, Harris Center, Veteran's Mental Health Care Line, Legacy Community Health Services, and DePelchin's Children's Center, will be involved with the program and the Mayor's Office of Education is the program manager of the grant.

"I created the Office of Education to support school districts in Houston because they are doing the essential work of guaranteeing that our next generation of adults is educated and ready for the future," says Mayor Sylvester Turner in the release. "The grant validates our efforts and more importantly will provide care on the frontlines of a key health issue involving young people."

Five independent school districts will also receive first level screening services and telemedical care. Families of the students receiving care will also receive support from the newly developed Texas State Child Mental Health Consortium.

"Houston and our surrounding area is primed to really take children's mental health care to the next needed level," says Williams in the release. "This SAMHSA grant opportunity coupled with the State Consortium will allow better coordination amongst services and an overall increase in available services — services that are desperately needed."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

NASA unveils Artemis III astronauts at Johnson Space Center in Houston

To the moon

NASA on Tuesday, June 9, revealed the crew for its Artemis III mission, the next step in the space agency's plan to eventually land astronauts on the moon.

The announcement came two months after Artemis II's record-breaking trip around the moon that surpassed the distance record of Apollo 13.

NASA's Randy Bresnik, Frank Rubio, Andre Douglas and the European Space Agency's Luca Parmitano won't fly to the moon or land on the surface. Instead, they’ll orbit Earth while practicing docking their Orion capsule with two lunar landers.

“To the Artemis III crew, we wish you Godspeed on the journey ahead,” said NASA administrator Jared Isaacman.

Elon Musk’s SpaceX and Jeff Bezos’ Blue Origin are racing to deliver the lunar landers. The two-week demo is targeted for 2027. Blue Origin suffered a recent setback when its massive rocket exploded during an engine-firing test on the launch pad in Florida, shaking nearby homes and illuminating the sky with an orange fireball.

NASA's Jeremy Parsons said the setback is a learning opportunity and that the space agency is confident Blue Origin's rocket will be ready in time.

NASA's Artemis program aims to return astronauts to the moon's surface for the first time since the 1970s. A recent revamp of the program announced by Isaacman aims to fast-track it similarly to the Apollo era, adding the upcoming spaceflight around Earth before eyeing a lunar landing in 2028.

“We are certainly humbled as a crew to be able to be your crew that executes this Artemis III mission in space,” said Bresnik, Artemis III commander.

Added Douglas, mission specialist: “My brain — it is going a mile a minute right now. But my heart, it is so warm. It is so full."

In May, NASA awarded hundreds of millions of dollars in contracts to four companies, including Blue Origin, to build landers, rovers and drones for a future moon base. Isaacman said the goal of the moon base is to lay the foundation for a Mars expedition.

Meta to bring $115 million AI data center training initiative to Houston

ai workforce

Meta and Associated Builders and Contractors have entered into a partnership to invest $115 million in training programs for the construction of AI data centers, with a portion of the project launching in Houston.

The companies announced June 8 that they would open America’s Workforce Academies at ABC chapter training centers in Houston; Indianapolis; Baton Rouge, Louisiana; and Columbus, Ohio.

The academies will offer career readiness and safety training, plus five weeks of hands-on education. Participants who complete the program will be granted a job offer from contractors working on Meta projects.

“The AI revolution is bringing change but also historic opportunities,” Dina Powell McCormick, Meta president and vice-chairman, said in a news release. “Skilled workers electrified rural America one pole at a time. They manned the factories that built the arsenal that won World War II. Now a new generation will pour the foundations and lay the fiber that secures American strength in this new age.”

Overall, the Meta and ABC aim for the academies to build a more sustainable pipeline of skilled construction workers and ensure safety and job readiness for the surging number of data center projects underway.

“This new program is an innovative talent solution that is a critical part of addressing the construction industry’s ongoing workforce shortage and creates an accelerated, new-entrant strategy for job seekers ... The sustained demand for data center construction technicians means the industry needs an all-of-the-above approach to address this shortage and grow the construction talent pool,” Michael Bellaman, ABC president and CEO, added in the release.

In Texas, Meta, the parent company of Facebook and Instagram, has launched or broken ground on data centers in El Paso, Fort Worth and Temple. The company announced in March that it planned to grow its El Paso Data center by 1 gigawatt, representing more than a $10 billion investment.

Apart from Meta, Texas has attracted data center development to power other giants like Google and Amazon in recent years. In turn, Texas has been predicted to become the biggest data center market. Commercial real estate services provider JLL reported this spring that the state could topple Northern Virginia as the world’s largest data-center market by 2030. Similarly, CBRE predicted that Houston's data center capacity could double by 2028. Read more here.

New Houston biotech co. lands $30M for pulmonary fibrosis drug

drug money

Most of us can claim a scar or two on our bodies. But when scarring develops inside the body, it’s known as a fibrotic disorder. A freshly launched Houston company, Oorja Bio Inc., is working on a treatment that can help to repair cells and reduce the damage wrought by the growth of fibrotic tissue in patients.

Late last month, Oorja Bio hit the scene with a pair of big announcements. Not only has the company raised a $30 million Series A thanks to founding investor California-based Westlake BioPartners, but it has also already paved the way for a Phase 2 study to take place this year.

Oorja Bio received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to test its treatment in patients with idiopathic pulmonary fibrosis (IPF), a scarring of the lung tissue. IPF affects more than 150,000 adults in the United States and can result in a range of symptoms from shortness of breath to organ failure and death as it progresses.

Oorja Bio’s lead drug candidate, ORJ-001, was shown in a Phase 1 in-human trial to demonstrate “therapeutically relevant exposure and favorable tolerability” in 64 healthy adult volunteers in whom it was administered daily or weekly, according to a news release. Pre-clinical studies of ORJ-001 showed durable target tissue engagement and biomarker activity in bleomycin-induced lung fibrosis.

Administered subcutaneously, ORJ-001 is intended to improve and even restore function in cells that can reduce the signaling that causes IPF. It stops advancement of IPF and also allows for tissue repair. Currently available treatments for the disease can slow the development of IPF down, but do not address the declining lung function that’s inherent in its progression.

“The clinical and preclinical results from our studies to date give us confidence that ORJ-001 represents a novel treatment approach with the potential to repair and reverse fibrosis and modify disease progression in IPF,” Dr. Janethe Pena, CMO of Oorja Bio, said in the release.

“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” CEO and founder Sujay Kango added. “As we advance ORJ-001 in the clinic, we are embracing the paradigm shift in our biological understanding of IPF pathology that aligns with the central role of the alveolar epithelium. ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”

Most patients live only three to five years following their IPF diagnosis. Soon, ORJ-001 and Oorja Bio could give them a fighting chance.

View All Listings